| Bid | 3.03 |
| Market Cap | 151.14M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -1.72 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.6 |
| Volume | 829,593 |
| Avg. Volume (20D) | 1,485,240 |
| Open | 3.23 |
| Previous Close | 3.20 |
| Day's Range | 3.13 - 3.35 |
| 52-Week Range | 1.38 - 4.50 |
| Beta | undefined |
About CKPT
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-...
Analyst Forecast
According to 3 analyst ratings, the average rating for CKPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 186.62% from the latest price.
3 weeks ago · seekingalpha.com
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's ApprovalCheckpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor ...
2 months ago · seekingalpha.com
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA DateCheckpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is...